EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SHP1‐Mediated FTO Dephosphorylation Regulates Mitophagy and Promotes Tumor Progression via N(6)‐Methyladenosine in Colorectal Cancer

Xi Wang, Qinyu Li, Kai Zeng, Weiheng Zhao, Mu Yang, Sibi Yin, Li Ma, Bo Liu iD, Hong Qiu, Chaofan Liu, Xianglin Yuan iD

MedComm · 2026-11 · 7 (11)

DOI: 10.1002/mco2.71140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MedComm, online erschienen am 08.11.2026. Verfasst von Xi Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) progression and resistance to therapy are driven by complex molecular mechanisms, implying the importance of identifying biomarkers and developing treatment strategies. Whereas Src homology region 2 domain‐containing phosphatase 1 (SHP1) is implicated in immune regulation, its role in tumor malignancy remains unclear. Here, we demonstrate that SHP1 is significantly upregulated in CRC tissues and correlates with poor prognosis. Mechanistically, SHP1 was found to dephosphorylate the N(6)‐methyladenosine (m6A) demethylase fat mass and obesity‐associated protein (FTO) at the Y475 tyrosine residue, thereby enhancing its enzymatic activity to reduce global m6A methylation levels. Integrated RNA sequencing and m6A profiling revealed that SHP1 depletion increased PTEN‐induced kinase 1 (PINK1) mRNA m6A modifications, promoting its degradation and suppressing mitophagy. SHP1 inhibitor TPI‐1 or siRNA–SHP1‐loaded lipid nanoparticles (LNPs) attenuated CRC cell proliferation, migration, and tumor growth in xenograft models through impaired mitochondrial homeostasis. These findings establish the SHP1–FTO–m6A axis as a critical regulator of mitophagy‐driven CRC progression. Clinically, our study highlights SHP1 as a prognostic biomarker and potential therapeutic target, with TPI‐1 and LNP–siSHP1 offering novel strategies for CRC management.

Schlagwörter

Stichwörter der Autor:innen

FTON(6)‐methyladenosineSHP1colorectal cancermitochondrial homeostasismitophagy

Autor:innen und Institutionen

  • Department of Oncology Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China.
  • Department of Urology the First Affiliated Hospital of Shihezi University Shihezi Xinjiang China.

ORCID-Profile: Bo Liu, Xianglin Yuan

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, X., Li, Q., Zeng, K., Zhao, W., Yang, M., Yin, S., Ma, L., Liu, B., Qiu, H., Liu, C., & Yuan, X. (2026). SHP1‐Mediated FTO Dephosphorylation Regulates Mitophagy and Promotes Tumor Progression via N(6)‐Methyladenosine in Colorectal Cancer. MedComm, 7(11). https://doi.org/10.1002/mco2.71140

Vancouver

Wang X, Li Q, Zeng K, Zhao W, Yang M, Yin S, et al. SHP1‐Mediated FTO Dephosphorylation Regulates Mitophagy and Promotes Tumor Progression via N(6)‐Methyladenosine in Colorectal Cancer. MedComm. 2026;7(11). doi:10.1002/mco2.71140

BibTeX
@article{Wang2026,
  author = {Wang, Xi and Li, Qinyu and Zeng, Kai and Zhao, Weiheng and Yang, Mu and Yin, Sibi and Ma, Li and Liu, Bo and Qiu, Hong and Liu, Chaofan and Yuan, Xianglin},
  title = {SHP1‐Mediated FTO Dephosphorylation Regulates Mitophagy and Promotes Tumor Progression via N(6)‐Methyladenosine in Colorectal Cancer},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {11},
  doi = {10.1002/mco2.71140}
}
Kostenlos starten →